Wall Street analyst estimates for Lakefront Biotherapeutics N.V. (LKFT): consensus price target and buy/hold/sell recommendations.
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (−2 sell to +2 buy) | 0.50 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.83 | ||
| 2026-08-10 | $0.03 | $-0.82 | +104.2% |
| 2026-05-06 | $0.25 | $-0.94 | +126.2% |
| 2026-02-23 | $13.90 | $-0.13 | +11077.7% |
| 2025-11-05 | $-3.54 | $-0.48 | -641.4% |
| 2025-07-23 | $-1.85 | $-0.23 | -711.8% |
| 2025-04-23 | $-2.67 | $-0.14 | -1783.0% |
| 2025-02-12 | $0.30 | $-0.55 | +155.1% |
Valuation Ratios
| P/E Ratio | 3.85 |
| Price / Book | 0.58 |
| EV / EBITDA | 5.16 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 234.4M EUR | 241.2M EUR | 239.7M EUR | 275.6M EUR | 1.11B EUR |
| Cost of Revenue | 320.5M EUR | 0 | 0 | 34.9M EUR | 29.7M EUR |
| Gross Profit | -86.1M EUR | 241.2M EUR | 239.7M EUR | 240.8M EUR | 1.08B EUR |
| Research & Development | 320.5M EUR | 269.8M EUR | 241.3M EUR | 335.5M EUR | 459.4M EUR |
| Selling, General & Admin | 131.5M EUR | 103.3M EUR | 94.3M EUR | 96.9M EUR | 112.0M EUR |
| Operating Expenses | 85.4M EUR | 372.3M EUR | 328.0M EUR | 429.1M EUR | 581.1M EUR |
| Operating Income | -171.6M EUR | -131.1M EUR | -88.3M EUR | -188.3M EUR | 501.4M EUR |
| EBITDA | -163.3M EUR | 3.9M EUR | 51.0M EUR | 43.3M EUR | 359.0M EUR |
| Interest Expense | 8.7M EUR | 9.2M EUR | 1.8M EUR | 911,000 EUR | 2.2M EUR |
| Pre-tax Income | -119.4M EUR | -70.8M EUR | 5.6M EUR | -3.1M EUR | 300.9M EUR |
| Income Tax | 1.4M EUR | 572,000 EUR | 9.6M EUR | -1.8M EUR | -18.6M EUR |
| Net Income | -103.2M EUR | -218.0M EUR | 211.7M EUR | 74.1M EUR | 320.9M EUR |
| EPS | $-1.84 | $-3.32 | $3.21 | $1.12 | $4.87 |
| EPS (Diluted) | $-1.84 | $-3.32 | $3.21 | $1.12 | $4.87 |
| Shares Outstanding (Diluted) | 65.5 M | 65.7 M | 65.9 M | 66.1 M | 65.9 M |
Price
| Price | $32.08 (closing price, October 28, 2026) |
| Market Cap | $2.1B |
| Exchange | NASDAQ |
| Country | BE |
Related companies: IOVA · SLS · VRTX · 0QZU.L · 0R2M.L · MRNA · REGN · ARGX
Explore sector: Healthcare · Biotechnology
More sections of LKFT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks